Beklometazon (When ATH A07EA07)

When ATH:
A07EA07

Characteristic.

Беклометазона дипропионат — белый или кремово-белый порошок без запаха, very little soluble in water; very soluble in chloroform, acetone and alcohol. Molecular weight 521,25.

Pharmacological action.
Anti-inflammatory, antiallergic, decongestant, antiasthmatic.

Application.

Bronchial asthma, chronic obstructive pulmonary disease, nasal allergy (seasonal and permanent), vasomotor rhinitis, recurrent nasal polyposis, juvenile rheumatoid arthritis, inflammatory bowel disease, dysphonia in systemic lupus erythematosus, persistent inflammation of the middle ear in children, bronchopulmonary dysplasia of newborn.

Contraindications.

Hypersensitivity, I trimester of pregnancy, lactation.

Restrictions apply.

Systemic infections, tuberculosis, herpetic eye disease, II and III trimester.

Pregnancy and breast-feeding.

It contraindicated in I trimester of pregnancy. Во II и III триместрах возможно, if the effect of therapy outweighs the potential risk to the fetus.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

At the time of treatment should stop breastfeeding.

Side effects.

Hoarseness, feeling sore throat, bronhospasticskie reaction, bouts of sneezing, rhinorrhea, dryness and irritation in the nose, nose bleed, atrophic rhinitis, ulceration of the nasal mucosa, perforation of the nasal septum, headache, dizziness, Cataract, increased intraocular pressure, leukocytosis (incl. neutrophilic), lymphopenia, eosinopenia, manifestations of Cushing, incl. Cushing's syndrome (when using high doses of), oropharyngeal candidiasis and aspergillosis, nasal candidiasis, eosinophilic pneumonia, hives, angioedema.

Cooperation.

It increases the effect of beta-agonists. Latest, in turn, enhance the anti-inflammatory properties beclomethasone (increase its penetration in the distal bronchi).

Overdose.

Exhibit symptoms of the hypothalamic-pituitary-adrenal insufficiency. Shows a temporary transfer to receiving systemic glucocorticoids, appointment of ACTH.

Dosing and Administration.

Bronchial asthma: inhalation, adults - 100 mcg 3-4 times a day or 200-400 mcg 2 once a day; in severe exacerbation of asthma and steroidna dependency — 250-500 µg 2-3 times a day with a further gradual reduction in the dose reaching the control of asthma symptoms. Children — 50-100 µg 2-4 times a day, It is possible to use in daily dose 800 g.

Nasal allergy: intranasally, adults and children over 6 years - 200 mcg in each nostril 2 once a day.

Precautions.

You can not apply for the relief of acute asthma attack. In the case of an acute asthma attack in response to the use of beclomethasone, it should be lifted immediately. If there is evidence of hypothalamic-pituitary-adrenal insufficiency should be continued inhalation, but be sure to monitor the level of the basal plasma cortisol (the function of the hypothalamic-pituitary-adrenal system usually normal in 1-2 days). The same control is necessary when using high doses of beclomethasone (1500 g and more). It is necessary to prevent contact with the eyes. When moderate to severe broncho-obstructive syndrome recommended 15-20 minutes before use inhaled bronchodilators. The effectiveness of treatment of allergic rhinitis, accompanied by abundant mucous discharge and severe swelling of the nasal passages, increased, while the use of vasoconstrictors. To reduce the likelihood of oropharyngeal candidiasis recommended inhaled before meals and after each inhalation, rinse your mouth.

When steroid-dependent asthma to use high doses (more 1000 mcg per day). Translation patients with bronchial asthma with systemic effects of glucocorticoids in the inhaled form of beclomethasone dipropionate should be implemented gradually: single-step abolition of unacceptable or too rapid dose reduction.

Cautions.

Before using the inhaler should be heated to room temperature.

Cooperation

Active substanceDescription of interaction
AцetazolamidFMR: antagonizm. Against the background of beclomethasone decreased diuretic effect and increased risk of hypokalemia.
PrednisoloneFMR: synergism. Increases (mutually) Chance of suppression of the hypothalamic-pituitary-adrenal system.
PrymydonFKV. FMR. It accelerates the degradation and weakening effects.
RitonavirFKV. May increase the plasma concentration of.
SomatropinFMR: antagonizm. Against the backdrop of declining growth stimulating effect of beclomethasone.
PhenytoinFKV. FMR. It accelerates the degradation and weakening effects.
PhenobarbitalFKV. FMR. It accelerates the degradation and weakening effects.


Back to top button